Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With:

  • Eleventh Circuit Affirms Jury Verdict of $2.5 Million for Mesh Device Plaintiff Despite Close Call on Statute of Limitations

    A case recently decided by the United States Court of Appeals for the Eleventh Circuit addresses the application of Florida’s statute of limitations in products liability cases involving vaginal mesh devices.

  • Elafibranor Tablets (Iqirvo)

    The U.S. Food and Drug Administration has approved an oral dual peroxisome proliferator-activated alpha and delta receptor agonist for the treatment of primary biliary cholangitis, formerly known as primary biliary cirrhosis. Elafibranor was granted an accelerated approval and an orphan designation.

  • Racial Inequities in Shared Decision-Making for Critically Ill Patients

    In this thematic analysis of a previously conducted randomized clinical trial, disparate shared decision-making behaviors were observed among meetings with white vs. Black caregivers of critically ill patients, illustrating opportunities for future clinician-level interventions.

  • Is Artificial Intelligence Coming for Your Job?

    A retrospective analysis of plain chest X-ray images in the medical record using deep learning in patients suitable for risk assessment for atherosclerotic cardiovascular disease (ASCVD) has shown similar results as the American College of Cardiology/American Heart Association ASCVD risk calculator for determining who is at sufficient risk to consider statin therapy.

  • Empagliflozin Post-Acute Myocardial Infarction

    A prespecified further analysis of the EMPACT-MI trial has shown that patients within two weeks of an acute myocardial infarction who are at risk for heart failure who receive empagliflozin compared to placebo have significantly fewer episodes of heart failure hospitalizations over a median follow-up of 18 months.

  • Constipation: Adult and Pediatric Considerations

    Constipation is a common diagnosis in the emergency department (ED) that has been steadily increasing in prevalence over the past several decades. As the morbidity and healthcare costs from this condition increase, it is important that ED physicians be aware of the workup, management, and potential complications of this common condition in adults and children alike.

  • STEMI Watch 2024 Is Here!

    Written with Mission: Lifeline® hospitals in mind, STEMI Watch 2024: Advancing Developments, Improving Outcomes provides physicians and staff with a concise and practical update on ST-segment elevation myocardial infarction (STEMI). In the eighth edition of this series, you'll gain valuable STEMI CME/CE while reviewing clinically relevant recommendations to improve consistency of cardiac care for patients.

  • Utility of Electromyography in the Diagnosis of Rhabdomyolysis

    Electromyography often is requested in the evaluation of a patient with rhabdomyolysis. It often shows evidence of “myopathy,” but muscle biopsies frequently are non-confirmatory, and genetic testing often is needed for a definitive diagnosis.

  • Acute Clinical Worsening Without MRI Changes in Multiple Sclerosis

    Patients with multiple sclerosis (MS) can have an acute clinical event suggestive of a relapse, but their magnetic resonance imaging (MRI) shows no corresponding changes (labeled by the authors as an acute clinical event with stable MRI [ACES]). These events have not been systematically analyzed. The authors reported that this number is significant, and a quarter of the relapses reported by patients fall under this category. Patients with ACES had higher relapse rates and a greater risk of transition to secondary progressive MS.

  • Are New-Onset Seizures Associated with SARS-CoV-2 Vaccines?

    In this meta-analysis, there was no statistically significant difference in the risk of new-onset seizure incidence between vaccinated individuals and placebo recipients in the 28-day post-injection period. Similarly, in the post-injection entire blinded phase (median follow-up 148, 121, and 43 days in three trials), no significant difference was observed between the vaccine and placebo recipients regarding the incidence of new developing seizures.